We analyzed ORAI1 and ABCB1 gene expression in these three ELN classes, and we observed a significant increase in ABCB1 in AML patient samples with adverse risk (one-way ANOVA (F(2.414) = 21.16, p < 0.0001)), while ORAI1 gene expression was downregulated in this ELN class (one-way ANOVA (F(2.414) = 7.547, p = 0.0006)) (Figure 2d,e). This evidence concerns the gene ABCB1 and acute myeloid leukemia.